MCID: LYM027
MIFTS: 55

Lymphopenia

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Lymphopenia

MalaCards integrated aliases for Lymphopenia:

Name: Lymphopenia 12 29 55 44 15 73
Lymphocytopenia 12 63

Classifications:



External Ids:

Disease Ontology 12 DOID:614
ICD10 33 D72.810
ICD9CM 35 288.51
MeSH 44 D008231
SNOMED-CT 68 48813009
UMLS 73 C0024312

Summaries for Lymphopenia

PubMed Health : 63 About lymphocytopenia: Lymphocytopenia (LIM-fo-si-to-PE-ne-ah) is a disorder in which your blood doesn’t have enough white blood cells called lymphocytes (LIM-fo-sites).These cells are made in the bone marrow along with other kinds of blood cells. Lymphocytes help protect your body from infection. Low numbers of lymphocytes can raise your risk of infection.Lymphocytopenia also is called lymphopenia.

MalaCards based summary : Lymphopenia, also known as lymphocytopenia, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and thymic dysplasia. An important gene associated with Lymphopenia is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Cisplatin and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Disease Ontology : 12 A leukopenia that is the condition of having an abnormally low level of lymphocytes in the blood.

Wikipedia : 76 Lymphocytopenia, or lymphopenia, is the condition of having an abnormally low level of lymphocytes in... more...

Related Diseases for Lymphopenia

Diseases related to Lymphopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 33.3 FOXP3 IFNG RAG1
2 thymic dysplasia 30.0 FOXP3 IL2RG IL7
3 autoimmune enteropathy 29.7 FOXP3 IL2RA
4 cytomegalovirus infection 29.0 IFNG IL2RA RAG1
5 cryptococcosis 28.9 IFNG SELL UNC119
6 pancreas adenocarcinoma 28.8 FOXP3 IFNG IL7
7 severe combined immunodeficiency 28.7 IL2 IL2RG IL7 IL7R RAG1
8 t-cell leukemia 28.6 FAS IL2 IL2RA LCK
9 adult t-cell leukemia 28.6 FAS FOXP3 IL2 IL2RA
10 pulmonary sarcoidosis 28.2 IFNG IL2 IL2RA
11 erythema multiforme 28.2 FASLG IFNG IL2
12 visceral leishmaniasis 28.0 FOXP3 IFNG IL2
13 graft-versus-host disease 27.9 FAS FASLG IFNG IL2
14 combined immunodeficiency, x-linked 27.8 CD3G IL2 IL2RA IL2RG IL7 IL7R
15 autoimmune disease 27.6 FAS FOXP3 IFNG IL2 IL2RA
16 acute graft versus host disease 27.6 FASLG IFNG IL2 IL2RA
17 omenn syndrome 27.6 FOXP3 IFNG IL2RG IL7R RAG1
18 alopecia areata 27.6 FASLG IFNG IL2 IL2RA
19 multiple sclerosis 27.0 FOXP3 IFNG IL2 IL2RA IL7 IL7R
20 malaria 26.3 CD55 FASLG FOXP3 IFNG IL2
21 diabetes mellitus 26.2 FAS FASLG FOXP3 IFNG IL2 IL2RA
22 common variable immunodeficiency 25.9 FAS FOXP3 IFNG IL2 IL2RA LCK
23 immunodeficiency 13 11.8
24 idiopathic cd4-positive t-lymphocytopenia 11.5
25 immunodeficiency, x-linked, with magnesium defect, epstein-barr virus infection, and neoplasia 10.9
26 immunodeficiency 50 10.9
27 immunodeficiency 14 10.9
28 immunodeficiency 17 10.9
29 sideroblastic anemia with b-cell immunodeficiency, periodic fevers, and developmental delay 10.9
30 short stature, microcephaly, and endocrine dysfunction 10.9
31 immunodeficiency 52 10.9
32 combined immunodeficiency and megaloblastic anemia with or without hyperhomocysteinemia 10.9
33 aplasia cutis congenita with intestinal lymphangiectasia 10.8
34 schimke immunoosseous dysplasia 10.8
35 reticular dysgenesis 10.8
36 neutropenia, severe congenital, 4, autosomal recessive 10.8
37 immunodeficiency 8 10.8
38 immunodeficiency 22 10.8
39 immunodeficiency 37 10.8
40 immunodeficiency 40 10.8
41 immunodeficiency 49 10.8
42 caplan's syndrome 10.6 FAS FOXP3
43 lymphoproliferative syndrome 2 10.5 IL2RA MAGT1 PIK3CD
44 type ii mixed cryoglobulinemia 10.5 FAS FASLG
45 lymphocytic gastritis 10.4 FAS FASLG
46 balo concentric sclerosis 10.4 IL2RA SELL
47 toxicodendron dermatitis 10.3 IL2 SELL
48 systemic lupus erythematosus 10.2
49 lupus erythematosus 10.2
50 lymphoma 10.1

Graphical network of the top 20 diseases related to Lymphopenia:



Diseases related to Lymphopenia

Symptoms & Phenotypes for Lymphopenia

MGI Mouse Phenotypes related to Lymphopenia:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 MAGT1 IL2RA G6PC3 PIK3CD IFNG FASLG
2 endocrine/exocrine gland MP:0005379 10.36 IL2RA G6PC3 PIK3CD IFNG FASLG IL2RG
3 immune system MP:0005387 10.3 LCK MAGT1 IL2RA G6PC3 PIK3CD IFNG
4 cellular MP:0005384 10.27 FAS PIK3CD IFNG FASLG IL2RG CD3G
5 homeostasis/metabolism MP:0005376 10.18 FAS G6PC3 IL2RA PIK3CD IL2RG IFNG
6 cardiovascular system MP:0005385 10.16 IL2 FOXP3 FAS PIK3CD IFNG FASLG
7 digestive/alimentary MP:0005381 10.13 IL2RA PIK3CD IFNG FASLG IL2RG IL2
8 liver/biliary system MP:0005370 9.92 FAS IFNG FASLG FOXP3 IL2 SELL
9 neoplasm MP:0002006 9.86 FAS IFNG FASLG IL2RG IL7R IL2
10 normal MP:0002873 9.76 FOXP3 MAGT1 FAS IL2RG IFNG FASLG
11 respiratory system MP:0005388 9.61 IL2RA IFNG FASLG IL2RG IL2 FOXP3
12 vision/eye MP:0005391 9.23 FAS IL2RA IFNG FASLG FOXP3 IL2

Drugs & Therapeutics for Lymphopenia

PubMedHealth treatment related to Lymphopenia: 63

If you have mild lymphocytopenia with no underlying cause, you may not need treatment. The disorder may improve on its own.If you have unusual infections, repeat infections, and/or infections that won't go away due to lymphocytopenia, you'll need treatment for the infections.If you have a disease or condition that's causing lymphocytopenia, your doctor will prescribe treatment for that illness. Treating the underlying problem will help treat the lymphocytopenia.

Drugs for Lymphopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
5
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576 3823
6
Adenosine Approved, Investigational Phase 4 58-61-7 60961
7 Respiratory System Agents Phase 4
8 N-monoacetylcystine Phase 4
9 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
11 Expectorants Phase 4
12 Antidotes Phase 4
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antioxidants Phase 4,Phase 3
15 Protective Agents Phase 4,Phase 3,Not Applicable
16 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Rho(D) Immune Globulin Phase 4,Phase 3
18 Mitogens Phase 4,Phase 2,Phase 1
19 gamma-Globulins Phase 4,Phase 3
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Not Applicable
21 Steroid Synthesis Inhibitors Phase 4,Phase 2
22 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2
23 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
24 Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
25 Hormones Phase 4,Phase 2,Phase 1,Not Applicable
26 Antacids Phase 4
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1,Not Applicable
28 Endothelial Growth Factors Phase 4
29 Immunoglobulins, Intravenous Phase 4,Phase 3
30 Antifungal Agents Phase 4,Phase 1,Phase 2,Not Applicable
31 Proton Pump Inhibitors Phase 4
32 Anti-Ulcer Agents Phase 4
33 tyrosine Nutraceutical Phase 4
34
Zinc Approved, Investigational Phase 3 7440-66-6 23994
35
Ribavirin Approved Phase 3 36791-04-5 37542
36
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
37
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
38
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
39
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
40
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
41
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
42
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
43
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
44
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
45
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
46 tannic acid Approved, Nutraceutical Phase 3
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
48 interferons Phase 3
49 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4 N-acetylcysteine
2 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4 pazopanib
3 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
4 Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis Completed NCT01321164 Phase 3 Fumaric acid esters
5 A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung Completed NCT01154140 Phase 3 treatment;treatment
6 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed NCT00278954 Phase 3
7 Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Completed NCT00387764 Phase 3 pazopanib
8 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3 Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water
9 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease Completed NCT00529568 Phase 3 eltrombopag;placebo
10 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease Completed NCT00516321 Phase 3 eltrombopag;placebo
11 The CRISIS Prevention Study Terminated NCT00395161 Phase 3 Metoclopramide;Zinc;Selenium
12 Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas) Unknown status NCT02772094 Phase 2
13 GVAX in Advanced Prostate Cancer Patients Made Lymphopenic Unknown status NCT00122005 Phase 1, Phase 2
14 Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients Completed NCT01368107 Phase 2 placebo;interleukin 7;interleukin 7;interleukin 7
15 Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer Completed NCT00771810 Phase 2 TXA127;TXA127;Placebo
16 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Completed NCT00405327 Phase 2
17 Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00634881 Phase 1, Phase 2
18 Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy Completed NCT00815321 Phase 2
19 A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) Completed NCT00517530 Phase 1, Phase 2 Obinutuzumab
20 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study Completed NCT00630786 Phase 1, Phase 2 Panitumumab;Conatumumab
21 Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Completed NCT01471782 Phase 1, Phase 2
22 Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma Completed NCT01394939 Phase 1, Phase 2 Irinotecan
23 EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer Completed NCT01008475 Phase 1, Phase 2 EMD 525797 250 mg;EMD 525797 500 mg;EMD 525797 750 mg;EMD 525797 1000 mg;Cetuximab;Irinotecan
24 A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) Completed NCT01357161 Phase 2 MK-1775;Placebo;paclitaxel;carboplatin
25 T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
26 [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Completed NCT01717391 Phase 2 fluorothymidine F 18
27 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2 Cetuximab and Lenalidomide
28 Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis Completed NCT02780167 Phase 2 PF-04965842;PF-04965842;PF-04965842;PF-04965842;Placebo
29 Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients Completed NCT01636778 Phase 2 SB-497115-GR
30 Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Completed NCT00284141 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
31 Gene Therapy for WAS Completed NCT01347346 Phase 1, Phase 2
32 Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) Completed NCT00885833 Phase 1, Phase 2 Fludarabine, Busulfan, Thymoglobulin
33 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
34 Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia Recruiting NCT03519464 Phase 2
35 Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide Recruiting NCT03139851 Phase 2 Cyclophosphamide 50mg;Pembrolizumab 100 MG in 4 ML Injection
36 Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH). Recruiting NCT03338998 Phase 2 BAF312;Placebo
37 EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer Recruiting NCT02001272 Phase 2 Paclitaxel + Carboplatin every 3 weeks;Carboplatin monotherapy every 3 weeks;Weekly Paclitaxel and Carboplatin
38 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer Recruiting NCT02571725 Phase 1, Phase 2 Olaparib;Tremelimumab
39 Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients Recruiting NCT03294486 Phase 1, Phase 2 Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)
40 Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant Recruiting NCT03330795 Phase 1, Phase 2
41 Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Recruiting NCT02179086 Phase 2 temozolomide
42 PD 0332991 and Cetuximab in Patients With Incurable SCCHN Recruiting NCT02101034 Phase 1, Phase 2 PD 0332991
43 Treatment With Tamoxifen in Cryptococcal Meningitis Recruiting NCT03112031 Phase 2 Tamoxifen;Amphotericin B;Fluconazole
44 Busulfan, Fludarabine, and Thiotepa Conditioning Regimen for Non Malignant Disease Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
45 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
46 A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Recruiting NCT03019809 Phase 2
47 Gene Therapy for WAS Follow-up Recruiting NCT02333760 Phase 1, Phase 2
48 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
49 Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Recruiting NCT01347242 Phase 1, Phase 2
50 Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata Active, not recruiting NCT02974868 Phase 2 PF-06651600;PF-06700841;Placebo

Search NIH Clinical Center for Lymphopenia

Cochrane evidence based reviews: lymphopenia

Genetic Tests for Lymphopenia

Genetic tests related to Lymphopenia:

# Genetic test Affiliating Genes
1 Lymphopenia 29

Anatomical Context for Lymphopenia

MalaCards organs/tissues related to Lymphopenia:

41
T Cells, Bone, Bone Marrow, Lung, B Cells, Liver, Prostate

Publications for Lymphopenia

Articles related to Lymphopenia:

(show top 50) (show all 616)
# Title Authors Year
1
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( 29502931 )
2018
2
Neonatal Alloimmune Thrombocytopenia With Amegakaryocytosis, B Lymphopenia, and Villitis. ( 29610181 )
2018
3
The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. ( 28963724 )
2018
4
Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. ( 29143923 )
2018
5
Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma. ( 29143922 )
2018
6
A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. ( 29482778 )
2018
7
The Severe Deficiency of the Somatotrope GH-Releasing Hormone/Growth Hormone/Insulin-Like Growth Factor 1 Axis of <i>Ghrh<sup>-/-</sup></i> Mice Is Associated With an Important Splenic Atrophy and Relative B Lymphopenia. ( 29928261 )
2018
8
Lymphopenia in atopic dermatitis patients treated with oral immunosuppressive drugs. ( 29526121 )
2018
9
Newborn screening using TREC/KREC assay for severe T and B cell lymphopenia in Iran. ( 29943473 )
2018
10
Lymphopenia and fumaric acid esters for psoriasis: a retrospective case series prompted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommendations. ( 29027699 )
2018
11
Atrophy of primary lymphoid organs induced by Marek's disease virus during early infection is associated with increased apoptosis, inhibition of cell proliferation and a severe B-lymphopenia. ( 29587836 )
2018
12
Risk factors for fingolimod-induced lymphopenia in multiple sclerosis. ( 29497558 )
2018
13
Erratum: Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. ( 29417951 )
2018
14
Calorie restriction induces reversible lymphopenia and lymphoid organ atrophy due to cell redistribution. ( 29804201 )
2018
15
Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia. ( 29725107 )
2018
16
Lymphopenia is associated with late onset Pneumocystis jirovecii pneumonia in solid organ transplantation. ( 29512868 )
2018
17
A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. ( 28961694 )
2018
18
Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML. ( 29948248 )
2018
19
Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. ( 29296636 )
2018
20
Dysplasia of Granulocytes in a Patient with HPV Disease, Recurrent Infections, and B Lymphopenia: A Novel Variant of WHIM Syndrome? ( 28512628 )
2017
21
What Does Screening Newborns for T-Cell Lymphopenia Find? ( 28888255 )
2017
22
Cryptococcal meningitis in apparently immunocompetent patients: association with idiopathic CD4+ lymphopenia. ( 29223998 )
2017
23
Depletion-Resistant CD4 T Cells Enhance Thymopoiesis During Lymphopenia. ( 28397358 )
2017
24
Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma. ( 28558844 )
2017
25
Systemic Intravenous Adoptive Transfer of Autologous Lymphokine-activated I+I^ T-Cells Improves Temozolomide-induced Lymphopenia in Patients with Glioma. ( 28668896 )
2017
26
The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. ( 28392551 )
2017
27
Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters. ( 28954274 )
2017
28
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth. ( 28695300 )
2017
29
Systemic inflammatory response syndrome-related lymphopenia is associated with adenosine A1 receptor dysfunction. ( 28495790 )
2017
30
Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. ( 27770395 )
2017
31
T-Cell Lymphopenia Detected by Newborn Screening in Two Siblings with an Xq13.1 Duplication. ( 28770187 )
2017
32
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpointA blockers (PD-1/PD-L1 inhibitors). ( 28826073 )
2017
33
PD-1 Controls Tonic Signaling and Lymphopenia-Induced Proliferation of T Lymphocytes. ( 29075267 )
2017
34
Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation. ( 29205270 )
2017
35
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. ( 28576902 )
2017
36
Predominance of CD4+ T Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma and Identification of a Subset of Patients With Peripheral B-Cell Lymphopenia. ( 28575178 )
2017
37
T-cell lymphopenia in 22q11.2 deletion syndrome: Relationship to cardiac disease. ( 28964704 )
2017
38
Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients. ( 28387753 )
2017
39
First Report of CD4 Lymphopenia and Defective Neutrophil Functions in a Patient with Amebiasis Associated with CMV Reactivation and Severe Bacterial and Fungal Infections. ( 28243230 )
2017
40
Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. ( 28736763 )
2017
41
Profound T-cell lymphopenia associated with prenatal exposure to purine antagonists detected by TREC newborn screening. ( 28065337 )
2017
42
Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma. ( 29022484 )
2017
43
Intestinal microbiota link lymphopenia to murine autoimmunity via PD-1(+)CXCR5(-/dim) B-helper T cell induction. ( 28443628 )
2017
44
Idiopathic T cell lymphopenia identified in New York State Newborn Screening. ( 28694137 )
2017
45
Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap? ( 28543950 )
2017
46
Susceptibility to Cryptococcal Meningoencephalitis Associated With Idiopathic CD4(+) Lymphopenia and Secondary Germline or Acquired Defects. ( 28638843 )
2017
47
Dosimetric Predictors of Treatment-related Lymphopenia induced by Palliative Radiotherapy: Predictive Ability of Dose-volume Parameters based on Body Surface Contour. ( 28740459 )
2017
48
Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. ( 29248170 )
2017
49
Distinct roles of T-cell lymphopenia and the microbial flora for gastrointestinal and CNS autoimmunity. ( 26740263 )
2016
50
TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. ( 26959227 )
2016

Variations for Lymphopenia

Expression for Lymphopenia

Search GEO for disease gene expression data for Lymphopenia.

Pathways for Lymphopenia

Pathways related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 CD3G CD55 CD59 FASLG IFNG IL2
2
Show member pathways
13.68 CD3G FAS FASLG IFNG IL2 IL2RA
3
Show member pathways
13.46 CD3G FAS FASLG IL2 IL2RA IL2RG
4
Show member pathways
13.4 FASLG IFNG IL2 IL2RA IL2RG IL7
5
Show member pathways
13.3 FAS FASLG IL2 IL2RA IL2RG IL7
6
Show member pathways
13.02 CD3G FAS FASLG IFNG IL2 PIK3CD
7
Show member pathways
12.97 FAS FASLG G6PC3 IL2 IL2RA IL2RG
8
Show member pathways
12.93 IL2 IL2RA IL2RG IL7 IL7R PIK3CD
9
Show member pathways
12.87 CD3G CD55 FAS FASLG FOXP3 IFNG
10
Show member pathways
12.81 CD3G FAS FASLG IFNG IL2 IL2RA
11
Show member pathways
12.78 IFNG IL2 IL2RA IL2RG LCK
12 12.78 FAS FASLG IFNG IL2 IL2RA IL2RG
13
Show member pathways
12.68 IFNG IL2 IL2RA IL2RG IL7 IL7R
14
Show member pathways
12.6 FAS FASLG IFNG IL2 LCK PIK3CD
15
Show member pathways
12.5 CD3G FAS IFNG IL2 LCK PIK3CD
16 12.49 CD3G IL2 IL2RA IL2RG LCK PIK3CD
17
Show member pathways
12.48 CD3G FOXP3 IFNG IL2 IL2RA IL2RG
18 12.48 FAS FASLG FOXP3 IFNG IL2 IL2RA
19
Show member pathways
12.44 CD3G IL2 IL2RA IL2RG LCK
20
Show member pathways
12.24 IL2 IL2RA IL2RG LCK PIK3CD
21
Show member pathways
12.21 CD3G IL2 IL2RA IL2RG
22
Show member pathways
12.18 FASLG G6PC3 IL7R PIK3CD RAG1
23
Show member pathways
12.16 IFNG IL2 IL2RA IL2RG LCK
24
Show member pathways
12.16 IFNG IL2 IL2RA IL2RG IL7 IL7R
25
Show member pathways
12.13 CD3G IL2 LCK PIK3CD
26
Show member pathways
12.05 IL2 IL2RA IL2RG LCK PIK3CD
27 11.99 IFNG IL2 IL2RA IL7R LCK
28 11.9 CD3G CD55 CD59 IL2RA IL7 IL7R
29 11.87 IFNG IL2 IL2RA IL7 IL7R
30
Show member pathways
11.84 FASLG FOXP3 IFNG IL2 IL2RA
31 11.83 IFNG IL2 IL7R SELL
32 11.73 FAS FASLG PIK3CD
33 11.65 FAS FASLG IFNG IL2
34
Show member pathways
11.59 IL2RA IL2RG IL7 IL7R
35
Show member pathways
11.56 FASLG FOXP3 IL2 IL2RA IL2RG LCK
36 11.56 CD59 IFNG IL2 IL2RA IL7 IL7R
37 11.53 IL2RA IL7R LCK
38 11.52 FOXP3 IFNG IL2 IL2RA IL2RG
39 11.47 IL2RG IL7R LCK RAG1
40
Show member pathways
11.42 CD3G FASLG IFNG IL2 IL2RA IL2RG
41 11.4 FAS FASLG IFNG
42 11.33 CD3G IFNG IL2 IL2RA
43 11.32 IFNG IL2 IL7
44 11.32 IL2RG IL7 IL7R RAG1
45 11.24 IFNG IL2 IL2RA IL2RG LCK
46
Show member pathways
11.22 CD3G FASLG IFNG IL2 IL2RA IL2RG

GO Terms for Lymphopenia

Cellular components related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.87 CD3G CD55 FAS FASLG IL2RG MAGT1
2 membrane raft GO:0045121 9.46 CD55 FAS FASLG LCK
3 cell surface GO:0009986 9.43 CD55 CD59 FAS FASLG IL2RA SELL
4 external side of plasma membrane GO:0009897 9.02 FASLG IL2RA IL2RG IL7R SELL
5 plasma membrane GO:0005886 10.03 CD3G CD55 CD59 FAS FASLG IL2RA

Biological processes related to Lymphopenia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.89 CD3G CD59 IFNG IL2RA IL7R
2 T cell receptor signaling pathway GO:0050852 9.86 CD3G FOXP3 LCK PIK3CD
3 adaptive immune response GO:0002250 9.83 CD3G IFNG IL2 PIK3CD RAG1
4 negative regulation of inflammatory response GO:0050728 9.8 FOXP3 IL2 IL2RA
5 cytokine-mediated signaling pathway GO:0019221 9.8 FASLG IL2 IL2RA IL2RG IL7 IL7R
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.78 FAS FASLG LCK
7 T cell activation GO:0042110 9.71 CD3G FOXP3 PIK3CD
8 extrinsic apoptotic signaling pathway GO:0097191 9.7 FAS FASLG IFNG
9 T cell differentiation GO:0030217 9.67 IL2 IL7R LCK PIK3CD
10 interleukin-7-mediated signaling pathway GO:0038111 9.65 IL2RG IL7 IL7R
11 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.63 FAS FASLG
12 T cell homeostasis GO:0043029 9.63 FOXP3 IL2RA RAG1
13 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.61 FAS FASLG
14 negative regulation of interleukin-17 production GO:0032700 9.59 FOXP3 IFNG
15 positive regulation of regulatory T cell differentiation GO:0045591 9.58 FOXP3 IL2
16 negative regulation of T cell apoptotic process GO:0070233 9.58 IL7R RAG1
17 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2 IL2RA IL2RG
18 necroptotic signaling pathway GO:0097527 9.57 FAS FASLG
19 negative regulation of T-helper 17 cell differentiation GO:2000320 9.55 FOXP3 IL2
20 regulation of T cell homeostatic proliferation GO:0046013 9.51 IL2 IL2RA
21 negative regulation of lymphocyte proliferation GO:0050672 9.5 FOXP3 IL2 IL2RA
22 positive regulation of T cell differentiation GO:0045582 9.46 IL2 IL2RA IL7 RAG1
23 immune response GO:0006955 9.28 FAS FASLG IFNG IL2 IL2RA IL2RG
24 regulation of regulatory T cell differentiation GO:0045589 9.26 FOXP3 IFNG IL2 IL2RA
25 immune system process GO:0002376 10.02 CD3G CD55 IL2 IL2RA PIK3CD
26 positive regulation of cell proliferation GO:0008284 10 FASLG IFNG IL2 IL7 IL7R

Molecular functions related to Lymphopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.71 FASLG IFNG IL2 IL7
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.61 IL2 IL2RA IL2RG
3 T cell receptor binding GO:0042608 9.32 CD3G LCK
4 glycosphingolipid binding GO:0043208 9.26 IL2 SELL
5 interleukin-2 binding GO:0019976 9.16 IL2RA IL2RG
6 interleukin-2 receptor activity GO:0004911 8.96 IL2RA IL2RG
7 interleukin-7 receptor activity GO:0004917 8.62 IL2RG IL7R
8 protein binding GO:0005515 10.3 CD55 CD59 FAS FASLG FOXP3 IFNG

Sources for Lymphopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....